Skip to content

Treatment-resistant major depression: Systematic review of comparative efficacy of electroconvulsive therapy and ketamine

Giullia Graeff Saldanha, Leonardo Locatelli, Izidione Antônio Miozzo Junior

Physiology International January 30, 2025 DOI: 10.1556/2060.2024.00410 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Randomized Peer reviewed
Population Patients with major depressive disorder
Interventions Ketamine Electroconvulsive Therapy
Topics Depression Esketamine Ketamine
Key findings ECT is more effective than ketamine for remission in major depressive disorder, but ketamine has a rapid onset of effect; both treatments are safe but require further long-term study.

Abstract

AbstractDepression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is a condition characterized mostly by low or depressed mood as well as difficulty experiencing emotions, whether positive or negative. Poor adherence has sparked the interest from both physicians and patients in these alternative therapeutic approaches. Ketamine and Electroconvulsive Therapy (ECT) are emerging as promising options.ObjectiveTo evaluate the results related to the efficacy and safety of the therapeutic use of ketamine within its various application methods and ECT in patients with MDD.MethodSystematic review that employed the PubMed database to collect the clinical trials that analyzed and compared the efficacy and safety of intramuscular ketamine, oral ketamine, and ECT in MDD. The files were screened by title and selected by reading the abstracts. The selected files were then read for a complete analysis according to the inclusion and exclusion criteria.ResultsSeven randomized clinical trials (RCT) were selected. Ketamine displayed potential in the treatment of MDD due to its rapid-onset effect, but ECT is even more effective in terms of remission. Both treatments are safe, but they involve long-term side effects that require further study.ConclusionExploring how the characteristics of individual patients affect the response to ketamine and ECT can propel the development of more personalized treatments. However, the lack of long-term studies on the efficacy and safety of these therapies highlights the need for more RCTs comparing ketamine and ECT in patients with MDD.

Comparable studies

Other systematic reviews and meta-analyses on ketamine for depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
The use of ketamine as an antidepressant: a systematic review and meta‐analysis People with major depressive disorder or bipolar disorder receiving ketamine infusion 2015 Meta-analysis n = 437

Explore topics

By condition and practice